Amikacin inhalation - Nektar Therapeutics/Bayer HealthCare

Drug Profile

Amikacin inhalation - Nektar Therapeutics/Bayer HealthCare

Alternative Names: Aerosolised amikacin; Amikacin inhale; BAY-416551; Inhaled amikacin; NKTR-061

Latest Information Update: 28 Oct 2015

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Developer Bayer HealthCare; Nektar Therapeutics
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gram-negative infections; Nosocomial pneumonia

Most Recent Events

  • 10 Dec 2015 Biomarkers information updated
  • 24 Nov 2014 Inhaled amikacin receives Qualified Infectious Disease Product (QIDP) designation from the FDA for Gram-negative nosocomial pneumonia
  • 16 Apr 2013 Phase-III clinical trials in Gram-negative infections (adjunctive treatment) in Latvia, Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, the Netherlands, Poland, Portugal, Romania, Russia, Singapore, Spain, Switzerland and United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top